All MSB holders, if they are smart, will consolidate and push a few funds into this now.
MSB has the big 2 to come and this was a test to get it passed at least, and unfortunately CYP is following those little steps that have been approved for a great unmet condition, but not a commercial defining medical condition.
I see myself buying into CYP in the future for sure, but there is not enough data yet an safety of iPSC technology and I am not the judge the FDA is.
I am already telling my sons, have a little in this.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
